Phase 1 trial testing single agent CUDC-907, a novel, oral dual inhibitor of histone deacetylase (HDAC) and PI3K: Initial assessment of patients with relapsed or refractory (RR) diffuse large B-Cell lymphoma (DLBCL), including double expressor (DE) lymphoma Meeting Abstract

  

Authors:	Younes, A.; Berdeja, J. G.; Patel, M. R.; Kelly, K. R.; Flinn, I. W.; Gerecitano, J. F.; Neelapu, S. S.; Copeland, A. R.; Akins, A.; Clancy, M.; Ma, A.; Sun, K.; Tian, Z.; Wang, J.; Viner, J.; Oki, Y.
Abstract Title:	Phase 1 trial testing single agent CUDC-907, a novel, oral dual inhibitor of histone deacetylase (HDAC) and PI3K: Initial assessment of patients with relapsed or refractory (RR) diffuse large B-Cell lymphoma (DLBCL), including double expressor (DE) lymphoma
Meeting Title:	57th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	126
Issue:	23
Meeting Dates:	2015 Dec 5-8
Meeting Location:	Orlando, FL
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2015-12-03
Language:	English
ACCESSION:	WOS:000368019001009
PROVIDER:	wos
DOI:	10.1182/blood.V126.23.257.257
Notes:	Meeting Abstract: 257 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/91491